BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) Meeting Abstract
| Authors: | Kirkwood, J. M.; Long, G. V.; Trefzer, U.; Davies, M. A.; Ascierto, P. A.; Chapman, P. B.; Puzanov, I.; Hauschild, A.; Robert, C.; Kefford, R.; Goodman, V. L.; Switzky, J. C.; Swann, R. S.; Martin, A. M.; Guckert, M. E.; Streit, M. R. W.; Schadendorf, D. |
| Abstract Title: | BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets) |
| Meeting Title: | 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 30 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2012 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2012-05-20 |
| Language: | English |
| ACCESSION: | WOS:000318009802809 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2012.30.15_suppl.8501 |
| Notes: | Meeting Abstract: 8501 -- Source: Wos |
